



## TCR<sup>2</sup> Therapeutics to Participate in Upcoming Conferences in August

August 6, 2019

CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- TCR<sup>2</sup> Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that management will participate in two upcoming investor conferences in August.

- Ian Somaiya, Chief Financial Officer of TCR<sup>2</sup> Therapeutics, will be available for one-on-one meetings at the BTIG Biotechnology Conference 2019 on August 12, 2019 in New York, NY
- Garry Menzel, Ph.D., President and Chief Executive Officer of TCR<sup>2</sup> Therapeutics, will present a company overview at the 2019 Webdush PacGrow Healthcare Conference on August 13, 2019 at 8:00am ET in New York, NY

A live webcast of the presentation will be available on the Investors page of the Company's website at [investors.tcr2.com](http://investors.tcr2.com). An archived replay will be available for at least 30 days following the presentation.

### About TCR<sup>2</sup> Therapeutics

TCR<sup>2</sup> Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR<sup>2</sup>'s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC™-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. For more information about TCR<sup>2</sup>, please visit [www.tcr2.com](http://www.tcr2.com).

### Investor and Media Contact:

Carl Mauch  
Director, Investor Relations and Corporate Communications  
(617) 949-5667  
[carl.mauch@tcr2.com](mailto:carl.mauch@tcr2.com)



Source: TCR2 Therapeutics